Sphera Funds Management LTD. Has $444,000 Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Sphera Funds Management LTD. lessened its position in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 52.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 118,758 shares of the company's stock after selling 129,893 shares during the quarter. Sphera Funds Management LTD. owned approximately 0.28% of Kyverna Therapeutics worth $444,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Kyverna Therapeutics by 53.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company's stock valued at $53,000 after buying an additional 4,990 shares in the last quarter. Integral Health Asset Management LLC lifted its position in shares of Kyverna Therapeutics by 75.0% in the fourth quarter. Integral Health Asset Management LLC now owns 350,000 shares of the company's stock valued at $1,309,000 after acquiring an additional 150,000 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in Kyverna Therapeutics by 2,225.0% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company's stock worth $1,728,000 after purchasing an additional 442,090 shares in the last quarter. Corton Capital Inc. purchased a new position in Kyverna Therapeutics in the 4th quarter valued at about $45,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Kyverna Therapeutics during the 4th quarter worth about $299,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on KYTX. HC Wainwright decreased their target price on shares of Kyverna Therapeutics from $6.00 to $4.00 and set a "neutral" rating on the stock in a research report on Thursday, April 3rd. Morgan Stanley decreased their price objective on Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Kyverna Therapeutics currently has an average rating of "Buy" and an average target price of $18.33.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ:KYTX traded down $0.17 during trading on Wednesday, hitting $2.23. The company's stock had a trading volume of 185,949 shares, compared to its average volume of 416,036. The company has a market capitalization of $96.16 million, a PE ratio of -0.65 and a beta of 2.17. Kyverna Therapeutics, Inc. has a fifty-two week low of $1.78 and a fifty-two week high of $16.64. The stock's 50-day moving average price is $2.13 and its two-hundred day moving average price is $3.23.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($1.03) EPS for the quarter, topping the consensus estimate of ($1.21) by $0.18. On average, equities analysts predict that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.